Scholarlink

<p>Effective biomarkers for predicting early recurrence (ER) (within one-year post-surgery) of hepatocellular carcinoma (HCC) are lacking. LZTR1, a known tumor suppressor, plays a role in HCC development. This study investigated the correlation between <i>LZTR1</i> expression and ER of HCC and its effects on HCC cells. Clinical data of 101 HCC patients were collected to evaluate tumor prognostic factors. ROC curve analysis was used to evaluate the predictive ability of <i>LZTR1</i> in HCC. Huh7 cells and SK-Hep-1 cells were used for cell experiments to observe the effects of knocking out <i>LZTR1</i> on tumor cell proliferation and metastasis. Cox analysis showed that alpha-fetoprotein (<i>P</i> = 0.010), <i>LZTR1</i> (<i>P</i> = 0.014), tumor number (<i>P</i> = 0.032), and portal vein tumor thrombus (<i>P</i> = 0.001) as independent factors associated with ER of HCC. The one-year recurrence-free rate of HCC patients with high <i>LZTR1</i> expression (≥ 1.7) was 73.2%, while that of patients with low <i>LZTR1</i> expression (&lt; 1.7) was 41.4% (<i>P</i> = 0.009). ROC curve analysis showed that <i>LZTR1</i> expression had early predictive value for HCC (AUC = 77.9%). In vitro <i>LZTR1</i> knockdown promoted HCC cell proliferation and metastasis. Mechanistically, <i>LZTR1</i> downregulation increased RAS protein expression, leading to MAPK pathway activation and enhanced epithelial-mesenchymal transition. In conclusions, this study revealed that <i>LZTR1</i> acts as a tumor suppressor in the pathological process of HCC. <i>LZTR1</i> expression might be used as an effective predictive marker for ER of HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LZTR1 expression as a novel predictive biomarker for early recurrence of hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月20日

查看全文
  • Xi Yu,
  • Shuqi Mao,
  • Yuying Shan,
  • Kedan Cen,
  • Caide Lu,
  • Yi Huang

摘要

Effective biomarkers for predicting early recurrence (ER) (within one-year post-surgery) of hepatocellular carcinoma (HCC) are lacking. LZTR1, a known tumor suppressor, plays a role in HCC development. This study investigated the correlation between LZTR1 expression and ER of HCC and its effects on HCC cells. Clinical data of 101 HCC patients were collected to evaluate tumor prognostic factors. ROC curve analysis was used to evaluate the predictive ability of LZTR1 in HCC. Huh7 cells and SK-Hep-1 cells were used for cell experiments to observe the effects of knocking out LZTR1 on tumor cell proliferation and metastasis. Cox analysis showed that alpha-fetoprotein (P = 0.010), LZTR1 (P = 0.014), tumor number (P = 0.032), and portal vein tumor thrombus (P = 0.001) as independent factors associated with ER of HCC. The one-year recurrence-free rate of HCC patients with high LZTR1 expression (≥ 1.7) was 73.2%, while that of patients with low LZTR1 expression (< 1.7) was 41.4% (P = 0.009). ROC curve analysis showed that LZTR1 expression had early predictive value for HCC (AUC = 77.9%). In vitro LZTR1 knockdown promoted HCC cell proliferation and metastasis. Mechanistically, LZTR1 downregulation increased RAS protein expression, leading to MAPK pathway activation and enhanced epithelial-mesenchymal transition. In conclusions, this study revealed that LZTR1 acts as a tumor suppressor in the pathological process of HCC. LZTR1 expression might be used as an effective predictive marker for ER of HCC.